GlassScriptPhysician profile
John B Rhodes
NPI 1023350816
$3,950.45
in general payments reported to CMS, 2019-2025
34 companies · $922 in 2025
The $922 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,092 · 2020: $177 · 2021: $335 · 2022: $284 · 2023: $491 · 2024: $650 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.11 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $957.64 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $433.87 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.18 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $339.12 | 2019-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $248.13 | 2019-2025 | |
| Boston Scientific Corporation | $200.18 | 2019 | |
| Medtronic, INC. | $192.88 | 2021-2022 | |
| Covidien LP | $162.42 | 2019 | |
| Gilead Sciences, INC. | $128.54 | 2023-2025 | |
| Qol Medical, LLC | $118.74 | 2020-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $103.52 | 2023-2025 | |
| Celgene Corporation | $77.60 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $73.20 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $72.76 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $55.48 | 2024-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $43.43 | 2019 | |
| Shire North American Group INC | $35.25 | 2019 | |
| Daiichi Sankyo INC. | $35.06 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $30.36 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $29.55 | 2023 | Linzess |
| Endo Pharmaceuticals INC. | $24.49 | 2019 | |
| Glaxosmithkline, LLC. | $23.16 | 2024 | Rotarix, Pediarix, Bexsero |
| Shield Therapeutics INC | $20.20 | 2023 | Accrufer |
| Fresenius Kabi USA, LLC | $19.76 | 2023 | Idacio |
| Aimmune Therapeutics, INC. | $16.91 | 2025 | Zenpep |
| Lilly USA, LLC | $16.73 | 2025 | Omvoh |
| Alnylam Pharmaceuticals INC. | $14.88 | 2025 | Givlaari |
| Braintree Laboratories, INC. | $14.56 | 2025 | Sutab, Suflave |
| Mallinckrodt Hospital Products INC. | $14.42 | 2023 | Terlivaz |
| Biocon Biologics INC | $14.26 | 2025 | Yesintek |
| Merck Sharp & Dohme LLC | $13.78 | 2024 | Dificid |
| Romark Laboratories, Lc | $13.75 | 2020 | |
| Valinor Pharma, LLC | $13.10 | 2023 | Movantik |
| Intercept Pharmaceuticals, INC. | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.